Prostate IQ®: Next Generation Prostate Cancer Screening
Above: The BioSpy Collection Device allows for painless blood collection in the clinic, home, or workplace, in three to four minutes per patient. Samples are stable at room temperature for up to 72 hours with the preloaded anticoagulant and serum separator gel. The device eliminates the need for a phlebotomist, centrifugation, and cold storage, with a 70% reduction in total time¹ vs. traditional lab draws.
Below: Pictured on the left is a traditional (500 milliliter) laboratory blood draw. On the right, the BioSpy blood collection microtainer contains 300 microliters, representing a 99.94% reduction in blood volume per patient.
Prostate IQ™ Advantages
Race Stratified
Prostate IQ™ is a next generation diagnostic test that stratifies risk based on ethnicity. Studies show that Caucasian, Hispanic, African American and Indigenous Americans have baseline PSA levels that vary up to 2 ng/mL. Prostate IQ™ delivers a personal risk assessment based on your genotypical and phenotypical data.
Age Stratified
Prostate IQ™ protects older and younger alike with an age-based risk assessment. Currently, most laboratories use a cutoff of 4 ng/mL for all patients. Depending on age (and ethnicity), and utilizing tens of thousands of published, peer-reviewed datapoints, Prostate IQ™ assesses your personal risk for prostate cancer.
Multiplexed Microsampling
Utilizing PCR based DNA amplification, Prostate IQ™ requires 5 µL of whole blood (one fifth of a drop of blood) allowing the BioSpy Reference Laboratory to test for multiple analytes on a single microtainer of blood.
